Preclinical Imaging of Therapy Response Using Metabolic and Apoptosis Molecular Imaging
- First Online:
- Cite this article as:
- De Saint-Hubert, M., Wang, H., Devos, E. et al. Mol Imaging Biol (2011) 13: 995. doi:10.1007/s11307-010-0412-z
- 143 Downloads
Early after therapy, 2-deoxy-2-[18F]fluoro-d-glucose ([18F]FDG) imaging is not always reliable due to the influx of inflammatory cells while apoptosis imaging offers a direct and early measurement of therapy effects. This study uses an improved apoptosis probe (99mTc-hAnxA5) in combination with [18F]FDG imaging to evaluate therapy response.
Daudi tumor tissue was implanted in the spleen of SCID mice. Treatment was performed with adriamycin and cyclophosphamide. Sequential [18F]FDG-positron emission tomography (PET) was acquired over 6 days and 99mTc-hAnxA5-SPECT was performed before and 1 day after therapy.
On day 1, therapy induced apoptosis was visualized with 99mTc-hAnxA5 without a measurable change in [18F]FDG uptake. [18F]FDG uptake decreased significantly on day 3 and was even more pronounced on day 6.
In this preclinical model, 99mTc-hAnxA5 imaging was able to detect apoptosis before metabolic changes were measured. These results confirm the value of apoptosis imaging for therapy response and give more insight in [18F]FDG imaging and its parameters to evaluate response.